Veradermics, Incorporated (MANE)
NYSE: MANE · Real-Time Price · USD
114.80
+9.54 (9.06%)
At close: May 5, 2026, 4:00 PM EDT
114.80
0.00 (0.00%)
After-hours: May 5, 2026, 4:10 PM EDT
Veradermics Earnings Call Transcripts
Fiscal Year 2026
-
Top-line results from a large phase II/III trial show VDPHL01 achieved significant hair growth and high patient satisfaction with a strong safety profile. Both once- and twice-daily regimens outperformed existing therapies, and market research indicates high intent to prescribe and use if approved.
-
A novel extended-release oral minoxidil tablet is advancing through phase III trials, showing rapid and robust hair growth with improved safety and convenience. The product targets a large, motivated market, leverages a strong IP portfolio, and is positioned for broad adoption through dermatology, primary care, and telehealth channels.